PD-008 Adding ramucirumab to second-line irinotecan, 5-fluorouracil and folinic acid (FOLFIRI) treatment for metastatic colorectal carcinoma (mCRC): resource utilization data from RAISE, a global, randomized, double-blind, multicenter phase 3 study

Annals of Oncology ◽

10.1093/annonc/mdw200.08 ◽

2016 ◽

Vol 27 ◽

pp. ii104

Author(s):

J. Kisro ◽

A. Cohn ◽

T. Yoshino ◽

E. Van Cutsem ◽

S. Hegewisch-Becker ◽

...

Keyword(s):

Colorectal Carcinoma ◽

Folinic Acid ◽

Resource Utilization ◽

Second Line ◽

Metastatic Colorectal Carcinoma ◽

Phase 3 ◽

Double Blind ◽

Multicenter Phase ◽

Utilization Data

Download Full-text

Adding Ramucirumab To Second-Line Irinotecan, 5-Fluorouracil and Folinic Acid (Folfiri) Treatment for Metastatic Colorectal Carcinoma (Mcrc): Resource Utilization Data from Raise, A Global, Randomized, Double-Blind, Multicenter Phase 3 Study

Value in Health ◽

10.1016/j.jval.2017.08.2552 ◽

2017 ◽

Vol 20 (9) ◽

pp. A871

Author(s):

P Brück ◽

J Kisro ◽

AL Cohn ◽

T Yoshino ◽

E Van Cutsem ◽

...

Keyword(s):

Colorectal Carcinoma ◽

Folinic Acid ◽

Resource Utilization ◽

Second Line ◽

Metastatic Colorectal Carcinoma ◽

Phase 3 ◽

Double Blind ◽

Multicenter Phase ◽

Utilization Data

Download Full-text

Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study

The Lancet Oncology ◽

10.1016/s1470-2045(15)70127-0 ◽

2015 ◽

Vol 16 (5) ◽

pp. 499-508 ◽

Cited By ~ 406

Author(s):

Josep Tabernero ◽

Takayuki Yoshino ◽

Allen Lee Cohn ◽

Radka Obermannova ◽

Gyorgy Bodoky ◽

...

Keyword(s):

Colorectal Carcinoma ◽

Second Line ◽

Metastatic Colorectal Carcinoma ◽

First Line ◽

Phase 3 ◽

Double Blind ◽

Multicentre Phase ◽

First Line Therapy ◽

Line Therapy

Download Full-text

Five-day continuous infusion of 5-fluorouracil and pulsed folinic acid in patients with metastatic colorectal carcinoma: An effective second-line regimen

Annals of Oncology ◽

10.1023/a:1008257603687 ◽

1997 ◽

Vol 8 (11) ◽

pp. 1163-1165 ◽

Cited By ~ 13

Author(s):

M. Streit ◽

U. Jaehde ◽

S. Stremetzne ◽

K. Ridwelski ◽

H. Kerz ◽

...

Keyword(s):

Colorectal Carcinoma ◽

Continuous Infusion ◽

Folinic Acid ◽

Second Line ◽

Metastatic Colorectal Carcinoma

Download Full-text

2108 Subgroup analysis by KRAS status in RAISE: A randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression during or following first-line combination therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine

European Journal of Cancer ◽

10.1016/s0959-8049(16)31030-9 ◽

2015 ◽

Vol 51 ◽

pp. S365

Author(s):

E. Van Cutsem ◽

R. Obermannova ◽

G. Bodoky ◽

J. Prausová ◽

R. García-Carbonero ◽

...

Keyword(s):

Colorectal Carcinoma ◽

Combination Therapy ◽

Folinic Acid ◽

Subgroup Analysis ◽

Phase Iii ◽

Metastatic Colorectal Carcinoma ◽

First Line ◽

Double Blind ◽

Kras Status ◽

Phase Iii Study

Download Full-text

PD-029 Baseline carcinoembryonic antigen (CEA) as a predictive factor of ramucirumab efficacy in RAISE, a second-line metastatic colorectal carcinoma (mCRC) phase 3 trial

Annals of Oncology ◽

10.1093/annonc/mdw200.29 ◽

2016 ◽

Vol 27 ◽

pp. ii113

Author(s):

T. Yoshino ◽

R. Obermannová ◽

G. Bodoky ◽

R. Garcia-Carbonero ◽

T.-E. Ciuleanu ◽

...

Keyword(s):

Colorectal Carcinoma ◽

Carcinoembryonic Antigen ◽

Predictive Factor ◽

Second Line ◽

Metastatic Colorectal Carcinoma ◽

Phase 3

Download Full-text

Review of RAISE, a Randomized, Double-Blind, Multicenter Phase III Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab (RAM) or Placebo (PBO) in Patients (pts) With Metastatic Colorectal Carcinoma (mCRC) Progressive During or Following First-Line Combination Therapy With Bevacizumab (bev), Oxaliplatin (ox), and a Fluoropyrimidine (fp): Primary Results and Subgroup Analysis by KRAS Status

Annals of Oncology ◽

10.1093/annonc/mdv340.05 ◽

2015 ◽

Vol 26 ◽

pp. vi37 ◽

Cited By ~ 2

Author(s):

A. Sobrero ◽

L. Latini ◽

C. Barone ◽

F. Capuzzo ◽

M. Banzi ◽

...

Keyword(s):

Colorectal Carcinoma ◽

Combination Therapy ◽

Subgroup Analysis ◽

Phase Iii ◽

Metastatic Colorectal Carcinoma ◽

First Line ◽

Double Blind ◽

Multicenter Phase ◽

Kras Status ◽

Phase Iii Study

Download Full-text

TheraSphere Yttrium-90 Glass Microspheres Combined With Chemotherapy Versus Chemotherapy Alone in Second-Line Treatment of Patients With Metastatic Colorectal Carcinoma of the Liver: Protocol for the EPOCH Phase 3 Randomized Clinical Trial

JMIR Research Protocols ◽

10.2196/11545 ◽

2019 ◽

Vol 8 (1) ◽

pp. e11545 ◽

Cited By ~ 7

Author(s):

Nikhil Chauhan ◽

Mary F Mulcahy ◽

Riad Salem ◽

Al B Benson III ◽

Eveline Boucher ◽

...

Keyword(s):

Clinical Trial ◽

Colorectal Carcinoma ◽

Randomized Clinical Trial ◽

Line Treatment ◽

Second Line ◽

Metastatic Colorectal Carcinoma ◽

Glass Microspheres ◽

Phase 3 ◽

Yttrium 90

Download Full-text

Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression

Annals of Oncology ◽

10.1093/annonc/mdw402 ◽

2016 ◽

Vol 27 (11) ◽

pp. 2082-2089 ◽

Cited By ~ 25

Author(s):

R. Obermannová ◽

E. Van Cutsem ◽

T. Yoshino ◽

G. Bodoky ◽

J. Prausová ◽

...

Keyword(s):

Colorectal Carcinoma ◽

Folinic Acid ◽

Subgroup Analysis ◽

Phase Iii ◽

Metastatic Colorectal Carcinoma ◽

Double Blind ◽

Phase Iii Study

Download Full-text

Second-line chemotherapy with weekly oxaliplatin and high-dose 5-fluorouracil with folinic acid in metastatic colorectal carcinoma: A Hellenic Cooperative Oncology Group (HeCOG) phase II feasibility study

Annals of Oncology ◽

10.1023/a:1008397109048 ◽

2000 ◽

Vol 11 (2) ◽

pp. 163-167 ◽

Cited By ~ 22

Author(s):

J. Janinis ◽

P. Papakostas ◽

G. Samelis ◽

D. Skarlos ◽

P. Papagianopoulos ◽

...

Keyword(s):

Colorectal Carcinoma ◽

Folinic Acid ◽

Feasibility Study ◽

Phase Ii ◽

High Dose ◽

Second Line ◽

Oncology Group ◽

Metastatic Colorectal Carcinoma ◽

Second Line Chemotherapy ◽

Line Chemotherapy

Download Full-text

Faculty Opinions recommendation of Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718451079.793497341 ◽

2014 ◽

Author(s):

Laurie Carr

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Disease Progression ◽

Stage Iv ◽

Small Cell ◽

Line Treatment ◽

Second Line ◽

Small Cell Lung ◽

Phase 3 ◽

Double Blind

Download Full-text